Defibrillation energy dose during pediatric cardiac arrest: Systematic review of human and animal model studies.

Resuscitation

Département de médecine familiale et médecine d'urgence, Université Laval, Pavillon Ferdinand-Vandry, 1050 Avenue de la Médecine, Québec, QC G1V 0A6, Local 4617, Canada.

Published: June 2019

Objective: To determine the initial defibrillation energy dose that is associated with sustained return of spontaneous circulation (ROSC) during paediatric cardiac arrest with ventricular fibrillation or pulseless ventricular tachycardia.

Methods: A systematic review was performed using four databases (PROSPERO: CRD42016036734). Human studies and animal model studies of pediatric cardiac arrest involving assessment of external defibrillation energy dosing were considered. The primary outcome was sustained ROSC. Survival and defibrillation-induced complications were also evaluated.

Results: The search strategy identified 14,471 citations of which 232 manuscripts were reviewed. Ten human and 10 animal model studies met the inclusion criteria. Human studies were prospective (n = 6) or retrospective (n = 4) cohort studies and included between 11 and 266 patients (median = 46 patients). Sustained ROSC rates ranged from 0 to 61% (n = 7). No studies reported a statistically significant association between the initial defibrillation energy dose and the rate of sustained ROSC (n = 7) or survival (n = 6). Meta-analysis was not considered appropriate due to clinical heterogeneity. Risk of bias was moderate. All animal studies were randomized controlled trials with 8 and 52 (median = 27) piglets. ROSC was frequently achieved (≥85%) with energy dose ranging from 2 to 7 J/kg (n = 7). The defibrillation threshold varied according to the body weight and appears to be higher in infant.

Conclusion: Defibrillation energy doses and thresholds varied according to the body weight and trended higher for infants. No definitive association between initial defibrillation doses and the sustained ROSC or survival could be demonstrated. Clinicians should follow local consensus-based guidelines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resuscitation.2019.04.028DOI Listing

Publication Analysis

Top Keywords

defibrillation energy
20
energy dose
16
sustained rosc
16
cardiac arrest
12
animal model
12
model studies
12
initial defibrillation
12
pediatric cardiac
8
systematic review
8
human animal
8

Similar Publications

Introduction: Effective defibrillation is essential to out-of-hospital cardiac arrest (OHCA) survival. International guidelines recommend initial defibrillation energies between 120 and 360 Joules, which has led to widespread practice variation. Leveraging this natural experiment, we aimed to explore the association between initial defibrillation dose and outcome following OHCA.

View Article and Find Full Text PDF

Background: Ventricular fibrillation (VF) is a vicious arrhythmia usually generated after removal of the aortic cross-clamp (ACC) in patients undergoing open-heart surgery, which could damage cardiomyocytes, especially in patients with left ventricular hypertrophy (LVH). Amiodarone has the prominent properties of converting VF and restoring sinus rhythm. However, few studies concentrated on the effect of amiodarone before ACC release on reducing VF in patients with LVH.

View Article and Find Full Text PDF

Purpose: Increasing life expectancy and advances in cancer treatment will lead to more patients needing both radiation therapy (RT) and cardiac implantable electronic devices (CIEDs). CIEDs, including pacemakers and defibrillators, are essential for managing cardiac arrhythmias and heart failure. Telemetric monitoring of CIEDs checks battery status, lead function, settings, and diagnostic data, thereby identifying software deviations or damage.

View Article and Find Full Text PDF
Article Synopsis
  • Stereotactic arrhythmia radioablation (STAR) has shown effectiveness for treating refractory ventricular tachyarrhythmia (VT), with a focus on a Taiwanese patient group.
  • The study involved 11 patients, using advanced imaging techniques to treat VT with a single radiation dose, resulting in a significant 88% reduction in VT episodes within the first six months post-treatment.
  • Despite initial success, many patients experienced late VT recurrence, with a one-year survival rate of 83%, leading to some requiring additional treatments such as heart transplants or HeartMate III implantation.
View Article and Find Full Text PDF
Article Synopsis
  • * The researchers have created a microscale soft flexible lithium-ion droplet battery (LiDB) made from biocompatible silk hydrogel that shows promise in biocompatibility, biodegradability, and high energy capacity.
  • * The LiDB has practical applications, such as powering molecule movement between synthetic cells and assisting in heart defibrillation and pacing, and can also serve as a mobile energy courier thanks to integrated magnetic particles.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!